Clinical Trials

266 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Nasopharyngeal Carcinoma

NCT02973386 2026-02-05

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Phase 3 Completed

294 enrolled

Nasopharyngeal Carcinoma

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07303023 2025-12-24

INCIPT-NPC

462 enrolled

Nasopharyngeal Carcinoma

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

166 enrolled

Nasopharyngeal Carcinoma

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Nasopharyngeal Carcinoma

NCT07201337 2025-11-17

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

550 enrolled

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT06118333 2025-09-30

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

386 enrolled

Nasopharyngeal Carcinoma

NCT04384627 2025-09-04

NPC-GTV

445 enrolled

Nasopharyngeal Carcinoma

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

10 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07072000 2025-07-18

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

550 enrolled

Nasopharyngeal Carcinoma

NCT04907370 2025-07-16

DIAMOND

532 enrolled

Nasopharyngeal Carcinoma

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT07000643 2025-06-03

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

386 enrolled

Nasopharyngeal Carcinoma

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

295 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

381 enrolled

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

296 enrolled 1 FDA

Nasopharyngeal Carcinoma

NCT06752239 2025-04-10

PROTECT-NPC

474 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma, Radiation Injuries, Thyroid Diseases

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

452 enrolled